RecruitingDepressive Disorder, Major

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Eligible age

18–75 yrs

Accepts

All genders

Locations

20 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months. The duration of study participation may vary and may be shortened if depression symptoms worsen or if withdrawal from the study occurs for any reason.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Meet the diagnostic criteria for major depressive disorder
✓ Are on a stable standard of care medication for major depressive disorder
✓ Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as
✓ self-inject study intervention
✓ store and use the provided blinded study intervention, as directed
✓ maintain electronic and paper study diaries, as applicable, and
✓ complete the required questionnaires